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Endothelial Dysfunction and Cytomegalovirus Replication in
Pediatric Heart Transplantation
Jacob Simmonds, MA, MB, MRCPCH; Matthew Fenton, MB, MRCPCH; Catherine Dewar, BSc;
Elizabeth Ellins, BSc, MA; Clare Storry, BSc, AVS; David Cubitt, PhD;
John Deanfield, MB, FRCP; Nigel Klein, PhD, FRCPCH;
Julian Halcox, MA, MD, FRCP; Michael Burch, MB, MD, FRCP, FRCPCH
Background—Cardiac allograft vasculopathy is the major limiting factor to the long-term success of pediatric heart
transplantation. Cytomegalovirus (CMV) has been shown to be a significant risk factor for the development of cardiac
allograft vasculopathy. Recent work has demonstrated CMV DNA in leukocytes in the absence of direct allograft
infection, suggesting that vascular changes may not be limited to the allograft.
Method and Results—Systemic arterial endothelial function was assessed with high-resolution ultrasound to determine
brachial artery flow-mediated dilation in 50 pediatric heart transplant recipients (8 to 17 years of age; 27 male). Patients
were separated into 2 groups according to CMV status: those without evidence of CMV replication after transplantation
(n38; 19 male) and patients with evidence of viremia after transplantation (n12; 8 male). No patient had detectable
viremia at the time of study. Flow-mediated dilation was significantly impaired in patients with evidence of CMV
replication after transplantation (6.641.12%, meanSE) compared with those without (9.480.56%; P0.02). This
difference remained after adjustment for age, time since transplantation, and medication. Pretransplantation recipient
and donor CMV status and traditional CMV risk were not associated with flow-mediated dilation.
Conclusions—CMV replication after cardiac transplantation is associated with chronic endothelial dysfunction in the
systemic circulation in children. The implication for both systemic and coronary vascular health requires prospective
evaluation. (Circulation. 2008;117:2657-2661.)
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Although short- and medium-term results are improving,long-term survival for pediatric transplant recipients is
limited by cardiac allograft vasculopathy, an accelerated form
of obliterative coronary disease. Human cytomegalovirus
(CMV) is associated with increased risk of posttransplanta-
tion coronary vasculopathy.1,2 We have shown CMV serol-
ogy to be an important factor in allograft vasculopathy of
pediatric recipients.3 Coronary endothelial dysfunction is
associated with CMV infection4 and the later development of
transplant vasculopathy.5 Recent work has shown that low-
level systemic CMV infection is common after transplanta-
tion,6 although infection of the heart itself is rare.7 It is
therefore possible that the coronary vascular disease attrib-
uted to CMV may be driven by the consequences of low-
grade systemic infection rather than infection of the trans-
plant organ, which may have broader vascular consequences.
However, the effect of posttransplantation CMV on the
systemic vasculature is unknown. We tested the hypothesis
that CMV replication could affect systemic endothelial func-
tion after pediatric cardiac transplantation.
Clinical Perspective p 2661
Methods
Study Population and Design
All children 8 years of age who had previously had a heart
transplant returning to Great Ormond Street Hospital for their annual
review between October 2004 and August 2006 were invited to take
part in the study. Exclusion criteria were coexisting vascular disease,
patient or parent refusal, active intercurrent systemic illness, and
clinical or echocardiographic evidence of heart failure (left ventric-
ular fractional shortening 30%). Fifty-two patients were invited, 2
of whom were excluded because of lack of parental consent. The
remaining 50 patients (age, 8 to 17 years; 27 male) were enrolled and
were separated into 2 groups based on CMV status: group 1 (n38;
19 male), those without evidence of CMV replication after trans-
plantation (negative polymerase chain reaction [PCR] and no change
in CMV IgG after transplantation), and group 2 (n12; 8 male),
patients with evidence of posttransplantation viremia (positive CMV
PCR and/or seroconversion from negative to positive CMV IgG). No
patient from either group was viremic at the time of assessment. All
patients were free of angiographic evidence of cardiac allograft
vasculopathy and were assessed for conventional vascular risk
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factors (hypertension, smoking, diabetes, lipid profile) and transplan-
tation and medication history.
Conventional and Transplantation-Related
Risk Factors
There were no smokers or diabetics among the cohort. There were no
significant differences between the groups with respect to age, sex,
heart rate, blood pressure, or blood glucose or lipid levels (Table 1).
Renal function, measured by serum creatinine and estimated glomer-
ular filtration rate (data not shown), was similar in both groups.
Transplantation-related variables and drug use were comparable
between the groups (Table 2). A double-therapy immunosuppressant
regimen of calcineurin inhibitor and a purine synthesis inhibitor was
used except when the latter was not tolerated, in which case a
single-agent therapy was used. No patients were receiving steroids at
the time of the scan. Eleven patients (7 in group 1, 4 in group 2) were
donor positive, recipient negative for CMV IgG at transplantation.
Of these, 6 (3 in group 1, 3 in group 2) received CMV prophylaxis
(valganciclovir 450 mg OD) for 3 months after transplantation.
Peripheral Endothelial Function
Measurement Methods
Endothelial dysfunction was studied as previously described.8
Briefly, the subjects rested supine for 10 minutes, having abstained
from caffeine and fatty food for 4 hours before the scan. The right
brachial artery was then imaged with high-resolution ultrasound
(Prosound SSD-5500, ALOKA, Tokyo, Japan). Forearm ischemia
was induced by inflating a blood pressure cuff to 200 mm Hg for 5
minutes; reactive hyperemia followed cuff deflation. Changes in
brachial artery diameter were measured offline with an automated
edge detection system (Brachial Tools, Medical Imaging Applica-
tions, Coralville, Iowa) and calculated as a percentage change from
baseline diameter. Blood flow was measured continuously with a
pulsed-wave Doppler signal. Maximal increase in blood flow within
15 seconds of cuff release was expressed as a percentage change
from baseline flow (SE). Endothelium-independent vasodilator
response to 25 g sublingual glyceryl trinitrate (GTN) was then
measured and expressed as a percentage change in diameter from
baseline. Blood pressure was initially taken after resting for 5
minutes and after flow-mediated dilation (FMD) and GTN studies
with an OMRON M5-I sphygmomanometer (OMRON, Kyoto,
Japan). All studies were performed in a temperature-controlled
vascular laboratory by a single trained operator who was blinded to
all clinical history of the patients, including CMV variables.
CMV Measurements
Blood for CMV analysis was taken before transplantation, at
monthly clinic visits after transplantation in the first year, and
annually thereafter. DNA was extracted from 200 L EDTA whole
blood with QI Amp Blood Mini Kits (catalog No. 80204, QIAGEN
Corp, Valencia, Calif) according to the manufacturer’s instructions.
CMV DNA was quantified in whole blood by a method developed by
J. Garson and R. Tedder at University College Hospital, London
(oral communication, 2003) that was standardized against samples
distributed by the European Quality Control for Molecular Diagnosis
program.
The master mix for the reaction consisted of 10 L Taqman
universal master mix (catalog No. 4304437, ABI Biosystems, Forest
City, Calif) for tests run on the ABI 7000 and 7300 machines or 10
L Taqman fast master mix (ABI catalog No. 4352042) for tests run
on the ABI 7500 machine: 1 L (10 pm/L) CMV forward primer,
GCA TGC GCG AGT GTC AAG AC; 1 L (10 pm/L) reverse
primer, GTT ACT TTG AG(CT) GCC ATC TGT TCC T; 2 L (10
pm/L) probe, FAM-TGC GCC GTA TGC TGC TCG ACA-
TAMRA; 1 L nuclease free water; and 10 L DNA template.
Cycling conditions were as follows: ABI 7000 and ABI 7300: 1
cycle at 50°C for 2 minutes, 1 cycle at 95°C for 10 minutes, 45
cycles at 95°C for 15 seconds, and a final step at 60°C for 1 minute;
and ABI 7500 fast machine: 1 cycle at 5°C for 20 seconds followed
by 45 cycles at 95°C for 3 seconds and a final step at 60°C for 30
seconds. Viral loads were obtained by reference to 10 CMV (strain
AD169 culture in human embryo lung fibroblasts) standards that
were included in each run, ranging from 100 to 2 million copies per
1 mL extract. Assays were considered valid if the correlation
coefficient for the standards was 0.99 and the gradient was
between 3.3 and 3.6. CMV IgG was measured by a Vidas
machine (bioMérieux, Marcy l’Etoile, France).
Table 1. Baseline Characteristics of Study Participants
Characteristics No CMV Replication CMV Replication P
Patients, n 38 12   
Age, y 14.50.4 13.10.6 0.071
Male sex, n (%) 19 (50) 8 (67) 0.322
Heart rate, median
(IQR), bpm
91 (79–104) 89 (84–97) 0.751
Systolic blood
pressure, mm Hg
1132 1103 0.534
Diastolic blood
pressure, mm Hg
711 653 0.065
Cholesterol, mmol/L 3.120.11 3.090.21 0.887
Triglycerides, mmol/L 0.880.06 1.010.14 0.291
HDL, mmol/L 1.020.05 1.030.07 0.962
LDL, mmol/L 1.730.11 1.590.19 0.551
Glucose, median
(IQR), mmol/L
5.10 (4.80–5.78) 5.20 (4.40–6.00) 0.596
hsCRP, median (IQR),
mg/L
0.86 (0.25–3.55) 0.45 (0.11–0.70) 0.108
Creatinine, mol/L 67.72.8 70.68.0 0.664
IQR indicates interquartile range; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; and hsCRP, high-sensitivity C-reactive protein. All blood
tests are fasting values. Values are expressed as meanSEM or frequency
(percentage) unless otherwise specified.
Table 2. Transplant-Related Variables
Characteristics No CMV Replication CMV Replication P
Age at transplant, median (IQR), y 11 (6–15) 9 (7–13) 0.555
Donor age, y 19.32.0 21.74.3 0.579
Ischemic time, min 19611 15618 0.081
Episodes of acute rejection, median (IQR), n 0 (0 – 1) 0 (0 – 1) 0.644
Time since transplant, median (IQR), y 3.63 (1.40–7.97) 2.68 (1.58–5.07) 0.674
Statin use, n (%) 34 (90) 9 (75) 0.337
Double immunosuppression, n (%) 34 (90) 10 (83) 0.621
IQR indicates interquartile range. Values are expressed as meanSEM or frequency (percentage) unless otherwise
specified.
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Statistical Analysis
Data were analyzed with SPSS 13.0 for Windows (SPSS Inc,
Chicago, Ill). Two-group comparisons of means were performed
with the unpaired Student t test for normally distributed data (age,
cholesterol, triglycerides, creatinine, blood pressure, donor age,
ischemic time, FMD, and dilatation to GTN) and the Mann–Whitney
U test for nonnormally distributed data (age at transplantation, time
since transplantation, episodes of acute rejection, heart rate, serum
glucose, and high-sensitivity C-reactive protein) after testing for
normality with the Kolmogorov-Smirnov test. Multiple-group com-
parisons were conducted with a 1-way ANOVA (CMV risk stratifi-
cation). Comparisons of proportions were calculated with Fisher’s
exact test (sex, medications). Linear regression with multiple pre-
dictors was performed to explore the relationship between CMV
status and FMD with adjustment for age, time since transplantation,
and medication.
The study was approved by the Great Ormond Street Hospital
Ethics Committee. Informed consent was obtained from all patients’
parents, and consent/assent was taken (as appropriate) from the
patients themselves.
The authors had full access to and take responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
Results
Vascular Function
No patients were CMV PCR positive at the time of the
brachial scan. The mean time from last positive PCR to scan
was 23 months, and only 2 patients had a positive PCR within
the 6 months before the scan. Brachial artery FMD was
significantly reduced in patients with previous active CMV
viremia after transplantation compared with patients without
evidence of replication (6.641.12% versus 9.480.56%;
P0.02; the Figure). This difference remained significant
when adjusted for age, time since transplantation, and med-
ication (P0.02). In contrast, response to GTN was compa-
rable between the 2 groups, indicating that the difference in
FMD was not due to differences in smooth muscle func-
tion. Baseline arterial diameter (2.960.079 versus
3.230.12 mm; P0.094) and flow (reactive hyperemia,
48941% versus 437128%; P0.618) also were similar in
groups 1 and 2.
The patients also were analyzed according to their donor
CMV status, recipient pretransplantation status, and tradi-
tional CMV risk stratification9 (Table 3). None of these 3
variables was predictive of FMD. There was no correlation
between maximum CMV PCR detected or duration of PCR
positivity and FMD.
Discussion
The present study is the first to link CMV and systemic
vascular dysfunction after heart transplantation. It demon-
strates that children with evidence of CMV replication after
heart transplantation (as shown by positive PCR or serocon-
version) have significantly worse systemic endothelial func-
tion. Although impaired endothelial dysfunction has been
described in children with symptoms of acute viral illnesses,10
our patients had neither signs of infection nor evidence of
CMV DNA in their blood at the time of vascular study,
suggesting a more chronic association between CMV and
vascular function. The relationship between active CMV
replication and reduced FMD remained after adjustment for
multiple potential confounding variables. The young age of
the cohort minimizes the impact of many of the potential
confounders for systemic vascular disease such as smoking,
hypertension, and diabetes. In addition, there was no relation-
ship to known risk factors such as inflammation (high-
sensitivity C-reactive protein), lipids, or blood pressure. This
abnormality in endothelial function may have important
implications for the later systemic vascular health of young
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Figure. FMD and GTN response (mean with SE) in group 1 (n38; no posttransplantation CMV replication) and group 2 (n12; positive
CMV PCR or seroconversion after transplantation).
Table 3. FMD Grouped by Pretransplantation CMV Variables
Criterion Value n FMD, % P
Donor CMV
status
Positive 19 9.030.89 0.911
Negative 29 8.900.67
Recipient CMV
status
Positive 15 8.820.72 0.840
Negative 33 9.060.70
Traditional risk
stratification
High risk 11 9.461.40 0.928
Intermediate risk 16 9.000.69
Low risk 20 8.950.85
High risk indicates donor CMV positive and recipient CMV negative;
intermediate risk, recipient CMV positive; and low-risk, donor and recipient
CMV negative. FMD values are meanSEM. The donor CMV status was not
available in 2 cases. The recipient’s pretransplantation status was not available
in 2 cases.
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transplant recipients and may reflect changes in the coronary
circulation of relevance to the pathogenesis of cardiac allo-
graft vasculopathy.
Although systemic vascular health clearly is important for
children after transplantation, it is coronary vasculopathy that
limits their long-term outcome.11,12 The pathogenesis of this
disease is complex, multifactorial, and currently incompletely
understood. However, studies have highlighted the relation-
ship between CMV and allograft vasculopathy in adults1,2,13
and, more recently, in children.3 One of the hallmarks of
allograft vasculopathy is endothelial dysfunction.5 Although
the mechanisms by which CMV may cause vasculopathy are
unknown, it is likely that dysfunction of the endothelium is
important. CMV has been shown to infect endothelial cells14
and is related to coronary vasomotor dysfunction in heart
transplantation patients.4 We have now extended these find-
ings to the systemic vasculature.
In previous adult studies, CMV-negative recipients of
CMV-positive hearts have shown an increased cardiovascular
risk.15,16 In our study, no relationship was seen between
systemic endothelial function and donor or recipient CMV
status, the traditional markers of risk of CMV disease. CMV
prophylaxis has reduced the risk of coronary disease in this
group.17 However, in most patients, no prophylaxis is given,
and CMV infection involving leukocytes remains common.6
Evidence is accumulating that graft vasculopathy may be
driven by the consequences of low-grade systemic infection
and reduced by its suppression.17 Pretransplantation CMV
seropositivity (and consequent lack of aggressive prophy-
laxis) appears to be associated with coronary lumen loss.18
This is consistent with our previous work on CMV and graft
vasculopathy in children3 and with our current findings in
which viral DNA was documented in patients CMV IgG
positive before transplantation. That subclinical CMV infec-
tion may have a systemic endothelial effect is further illus-
trated by our finding that 11 of the 12 children with
posttransplantation CMV replication did not go on to develop
overt CMV disease yet showed reduced systemic endothelial
function.
A recent study by Tu et al13 has investigated the immune
response to subclinical CMV infection in recipients who were
CMV IgG positive at transplantation. This study showed that
patients with CMV-specific CD4 t cells in the first month
after transplantation showed less coronary artery lumen loss
than those without these cells. These “early responders” also
were found to have low or undetectable levels of CMV by
PCR (mean, 40 copies per 1105 polymorphonuclear cells
compared with 250 copies per 1105 polymorphonuclear
cells in those without the early response). Although our study
was not designed to explore t-cell responses and the study
populations are different in terms of CMV status at transplan-
tation, it is probable that there is overlap of our group without
detectable virus and the early responder group of Tu et al. We
hypothesize that similar immune mechanisms may be work-
ing in our study, protecting against systemic vascular injury.
A follow-up project investigating immune responses and
systemic arterial function is required to explore this theory in
detail. However, both our results and the work by Tu et al
demonstrate that subclinical CMV infection is associated
with later vascular abnormalities and that those without
evidence of viral replication have a more favorable vascular
outcome.
The precise mechanism by which prior CMV replication
causes ongoing endothelial dysfunction is unclear. It is
possible that low-level CMV viremia (undetectable by cur-
rent assays) or persistent infection of leukocytes or endothe-
lial cells affects the vasculature directly. Alternatively, either
of these mechanisms may impair endothelial function indi-
rectly through chronic immune activation. It also is possible
that our observations are a lasting consequence of a prior
endothelial insult sustained at a time of higher viral load.
Quantification of endothelial function with ultrasound
assessment of brachial artery FMD is a well-validated,
noninvasive method. Recently, the first large, prospective
study has shown FMD to be predictive of future cardiovas-
cular events in adults.19 The prognostic value in younger
patients remains unproven because the cardiovascular end
points typically present decades later. FMD also is predictive
of coronary endothelial function in adults,20 raising the
possibility that depressed FMD in these children reflects
impaired coronary endothelial function relevant to the pro-
gression of cardiac allograft vasculopathy. Certainly, a non-
invasive marker of transplant coronary vasculopathy would
be diagnostically attractive, particularly in the pediatric age
group. Furthermore, because FMD is a dynamic measure-
ment, it may be useful as a therapeutic marker in clinical trials
assessing the response to CMV infections in the transplanta-
tion population.
All children in the present study had angiographically
normal coronary arteries, although a more sensitive assess-
ment of the coronary vasculature such as intravascular ultra-
sound would have been useful. Although this technique is
limited by the size of coronary arteries in young children, it is
possible in older children and adolescents. The monitoring of
CMV viral load was limited to outpatient visits, and it is
possible that some patients could have experienced low-level
CMV replication that was not detected; we accounted for this
possibility in part by checking for seroconversion in those
patients who were CMV negative at transplantation.
Conclusion
We have shown that CMV replication after cardiac transplan-
tation is associated with chronic endothelial dysfunction in
the systemic circulation in children. The implication for both
systemic and coronary vascular health requires prospective
evaluation.
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CLINICAL PERSPECTIVE
Cardiac allograft vasculopathy, the major limiting factor to the long-term success of pediatric heart transplantation, is
associated with the development of endothelial dysfunction in the donor coronary arteries. Cytomegalovirus (CMV) has
been shown to be a significant risk factor for the development of cardiac allograft vasculopathy. Recent work has
demonstrated CMV DNA in leukocytes in the absence of direct allograft infection, suggesting that vascular changes may
not be limited to the allograft. The present project used flow-mediated dilation in the brachial artery to illustrate decreased
native endothelial function in children who had shown CMV replication after heart transplantation. Importantly, none of
the patients enrolled in the present study were CMV DNA polymerase chain reaction positive at the time of their scan, and
only 1 developed clinical CMV disease. In addition, it was interesting to note that neither the pretransplantation CMV
status of donor or recipient nor CMV mismatch was associated with changes in brachial endothelial function. The present
work demonstrates that the effects of posttransplantation CMV are not limited to the allograft and that traditional risk
factors for CMV disease may not be adequate to identify those patients who are most likely to suffer CMV-mediated
complications. It also promotes the idea that subclinical CMV replication may be an important influence on later vascular
health, even after virus is no longer detectable in the blood. Further studies are required to prove a link between systemic
endothelial dysfunction and the later development of cardiac allograft vasculopathy in these patients.
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